Dana-Farber Cancer Institute: Targeted Drug Achieves 43% Response Rate in KRAS-Mutated Lung Cancer
June 04, 2022
June 04, 2022
BOSTON, June 4 (TNSjou) -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Experimental drug adagrasib also shows activity in lung cancer metastases to the brain
* * *
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized f . . .
* * *
Experimental drug adagrasib also shows activity in lung cancer metastases to the brain
* * *
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized f . . .